Three sets of diagnostic criteria for major depression and correlations with serotonin-induced platelet calcium mobilization in cancer patients

Uchitomi, Yosuke; Kugaya, Akira; Akechi, Tatsuo; Nakano, Tomohito; Wenner, Marcus; Okamura, Hitoshi; Takebayashi, Minoru; Kagaya, Ariyuki; Saeki, Toshinari; Yamawaki, Shigeto

doi:10.1007/s002130000583

Cited by 13 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results support previous studies that showed removing somatic items reduced the rates of depression in people with cancer (Grassi & Rosti, 1996; Ryan et al, 2012; Uchitomi et al, 2001). However, our results support the continued use of somatic symptoms in the assessment of depression with caution when sleep disturbance or fatigue is reported during active treatment.…”

Section: Discussionsupporting

confidence: 92%

“…These studies suggest that utilizing substitutive or exclusive criteria leads to lower prevalence of MDD than DSM-IV criteria (Grassi & Rosti, 1996; Ryan, Gallagher, Wright, & Cassidy, 2012; Uchitomi et al, 2001). However, some studies suggest somatic symptoms may still provide useful information especially for screening (Akechi et al, 2009; Mitchell, Lord, & Symonds, 2012; Traeger et al, 2011).…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

A differential item function analysis of somatic symptoms of depression in people with cancer

Ludman

McCorkle

Reid

et al. 2015

Journal of Affective Disorders

View full text Add to dashboard Cite

Background The overlap of somatic symptoms of depression with symptoms of cancer treatment is widely acknowledged and studied. However, this literature provides little guidance for clinicians as to whether these items should be used in assessing depression. The current study examined the appropriateness of using somatic items for assessment of depression in people with cancer. Methods People with newly diagnosed breast, lung or colorectal cancer (n=251) completed the Patient Health Questionnaire-9 (PHQ9) shortly after cancer diagnosis but before cancer treatment (baseline), 4 months later, typically during or shortly after treatment, and 12 months later. Pharmacy data was used to classify participants as having low somatic symptoms or high somatic symptoms. Differential item function (DIF) compared the functioning of the somatic items of the PHQ9 in the low vs. high symptom groups and the chemotherapy vs. no chemotherapy groups at the 4-month assessment. Results Significant DIF was not found on any of the four somatic items of the PHQ9 and differences in the item parameters of the somatic items was not consistent across the groups. However, fatigue and sleep indicated only mild depression. Only removing the fatigue item greatly affected the number screening positive for depression at 4 months (8.3%) but removing the other somatic items did not have as large an effect. Only one participant at baseline screened positive for depression by somatic symptoms alone (no psychological symptoms) and no participants screened positive by somatic symptoms alone at 4 months and 12 months. Limitations The sample size was small for DIF and consisted of mostly women with breast cancer. Conclusions Somatic symptoms of depression can continue to be administered to people with cancer, however the fatigue and sleep items should be used with caution.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 96%

A differential item function analysis of somatic symptoms of depression in people with cancer

Ludman

McCorkle

Reid

et al. 2015

Journal of Affective Disorders

View full text Add to dashboard Cite

show abstract

“…Delisi et al [239] found that the increase in the 5HT 2A receptor-mediated Ca 2+ response was greater in platelets of depressed patients with higher anxiety than those with low anxiety. The importance of Ca 2+ in depression is further supported by recent studies showing increased serotonin-induced Ca 2+ mobilization in platelets of depressed patients [240,241]. On the other hand, Kusumi et al [242] recently showed that depressed patients with an enhanced Ca 2+ response to 5HT in platelets exhibit a good response to mood stabilizers (bipolar patients) but that those with major depression showed a poor response to antidepressants.…”

Section: Calcium Regulation In Mood Disordersmentioning

confidence: 93%

The Concept of Dysregulated Signal Transduction and Gene Expression in the Pathophysiology of Mood Disorders

Dwivedi¹

2005

CPSR

View full text Add to dashboard Cite

Novel mechanistic concepts of the neurobiology of depression and bipolar disorder are evolving based on recent pre-clinical and clinical studies. Ongoing research could lead not only to a breakthrough in identifying the causative factors associated with mood disorders but also to the development of novel therapeutic interventions. One such recent breakthrough concerns the observed abnormalities in the two major signal transduction mechanisms most implicated in mood disorders: adenylyl-cyclase cyclic adenosine monophosphate (AC cAMP) and phosphoinositide (PI) hydrolysis. Among them are abnormalities in GTP binding proteins, phosphorylating enzymes, and substrate molecules observed in peripheral tissues and postmortem brain. More recently, cell survival pathways, such as the extracellular signal-regulated kinase and the Wnt pathways, which also cross-talk with AC-cAMP and PI signaling, have been investigated to elucidate their roles in the pathophysiology of mood disorders. Important consequences of the activation of these diverse signaling pathways are a modulation in the activation of transcription factors and, ultimately, in the regulation of gene expression. Particular attention is being paid to the roles of the transcription factor cAMP-response element binding protein and its target gene, brain-derived neurotrophic factor. Moreover, newer technologies, including complementary DNA microarray analysis, are revealing novel genes relevant to mood disorders. This critical overview presents our own and other groups' findings on various aspects of these signal transduction mechanisms, and on the regulation of gene expression, relevant to the pathophysiology of mood disorders.

show abstract

“…Diminished activity of forskolin-stimulated platelet adenylyl cyclase [48] has also been observed. Additionally, enhanced 5-HT-induced platelet calcium mobilization can be used as a biological marker when investigating the pathophysiology of major depression [49]. Other platelet receptors, such as the glutamate receptors, may work at a higher level of sensitivity in depression, too.…”

Section: Depression and Plateletsmentioning

confidence: 99%

Selective Serotonin Reuptake Inhibitors: Future Treatment of Vascular Disease?

Malinin

Atar

Serebruany³

2001

Heart Drug

View full text Add to dashboard Cite

There is substantial clinical evidence today that the incidence of depression and mortality after acute coronary syndromes are strongly related. The main effectors of coronary thrombosis are platelets, and hence, alterations of platelets and their functional characteristics may represent a conceptual bridge between these events. Selective serotonin reuptake inhibitors (SSRI), such as sertraline, have become an established therapy in patients with depression. These drugs provide not only a safe blockade of serotonin reuptake in the brain, but also in platelets, thus potentially protecting them from activation. However, the ability of sertraline therapy to deliver clinically meaningful antiplatelet effects and reduce thrombotic events, particularly acute coronary syndromes, is yet unexplored. Nevertheless, the platelet-related properties of SSRI may strongly affect the incidence of complications in patients with ischemic heart disease. Moreover, even marginal clinical benefits, together with recently reported severe bleeding events in some patients receiving oral platelet glycoprotein IIb/IIIa therapy, may potentially advance sertraline as a safe and efficient adjunct to the current therapeutic approach to the acute coronary syndrome. Further well-designed and carefully conducted clinical trials should elucidate the potential benefits of SSRI in an expanding array of clinical conditions, including myocardial infarction and unstable angina, with a prospect of SSRI to become suitable drugs, for example, in the convalescent phase of an ischemic event.

show abstract

Three sets of diagnostic criteria for major depression and correlations with serotonin-induced platelet calcium mobilization in cancer patients

Cited by 13 publications

References 24 publications

A differential item function analysis of somatic symptoms of depression in people with cancer

A differential item function analysis of somatic symptoms of depression in people with cancer

The Concept of Dysregulated Signal Transduction and Gene Expression in the Pathophysiology of Mood Disorders

Selective Serotonin Reuptake Inhibitors: Future Treatment of Vascular Disease?

Contact Info

Product

Resources

About